Inogen (NASDAQ:INGN) Issues Earnings Results, Beats Estimates By $0.14 EPS

Inogen (NASDAQ:INGN) released its quarterly earnings data on Tuesday. The medical technology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.14, Briefing.com reports. The business had revenue of $78.03 million for the quarter, compared to analysts’ expectations of $73.67 million. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.63) EPS.

Inogen Stock Performance

INGN stock opened at $8.24 on Thursday. The business’s 50-day moving average is $7.11 and its two-hundred day moving average is $6.51. The company has a market cap of $194.03 million, a price-to-earnings ratio of -1.87 and a beta of 1.10. Inogen has a fifty-two week low of $4.13 and a fifty-two week high of $11.98.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on INGN shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday. Stifel Nicolaus raised their price target on shares of Inogen from $6.00 to $7.00 and gave the company a “hold” rating in a report on Wednesday. Finally, William Blair raised shares of Inogen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Inogen presently has a consensus rating of “Hold” and a consensus target price of $7.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.